Dme Capital Management, LP Roivant Sciences Ltd. Transaction History
Dme Capital Management, LP
- $2.18 Trillion
- Q1 2024
A detailed history of Dme Capital Management, LP transactions in Roivant Sciences Ltd. stock. As of the latest transaction made, Dme Capital Management, LP holds 4,190,490 shares of ROIV stock, worth $44.9 Million. This represents 2.02% of its overall portfolio holdings.
Number of Shares
4,190,490Holding current value
$44.9 Million% of portfolio
2.02%Shares
1 transactions
Others Institutions Holding ROIV
# of Institutions
265Shares Held
489MCall Options Held
565KPut Options Held
1.68M-
Sb Investment Advisers (Uk) LTD London, X073MShares$783 Million7.6% of portfolio
-
Viking Global Investors LP69.4MShares$744 Million2.78% of portfolio
-
Qvt Financial LP New York, NY66.7MShares$715 Million65.04% of portfolio
-
Black Rock Inc. New York, NY36.2MShares$388 Million0.01% of portfolio
-
Morgan Stanley New York, NY35.6MShares$382 Million0.03% of portfolio
About Roivant Sciences Ltd.
- Ticker ROIV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 704,382,976
- Market Cap $7.55B
- Description
- Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne...